Diagnostic yield and psychological outcomes among women pursuing trio‐exome sequencing: Do women with recurrent anomalous fetal phenotypes experience more negative psychological outcomes?
Prenatal Diagnosis · 2023
DOI: 10.1002/pd.6318 ↗Kurz gefasst
Fachartikel in der Zeitschrift Prenatal Diagnosis, 2023. Verfasst von Asha N Talati und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, University of North Carolina School of Medicine, Chapel Hill, North Car…. Hauptthemen laut MEDLINE: Prenatal Care, Fetus. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NICHD NIH HHS, Eunice Kennedy Shriver National Institute of Child Health and Human Development.
Abstract (Originalsprache)
Purpose
To describe psychological outcomes among people with recurrent anomalous pregnancies pursuing trio‐exome sequencing (exome sequencing (ES)) compared to those with one affected.
Methods
We analyzed data from a prospective ES cohort, enrolling patients with major fetal anomaly and normal microarray. Participants completed validated scales before and after ES. We (1) compared responses of those with multiple anomalous pregnancies to those with one affected and (2) conducted linear regression to examine associations between multiple affected pregnancies and post‐ES constructs.
Results
Of 166 trios, 61 (37%) received results from ES. Forty (24%) had more than one affected pregnancy and 45% of those received a result explaining the fetal phenotype. All participants had clinically significant presequencing generalized psychological distress. For the 93 who completed the post‐ES surveys, those with multiple affected pregnancies had higher psychological adaptation scores but worse test related distress scores (9.3 (6.2) versus 7.1(5.6), p = 0.12) and (14.3 (1.5) versus 15.4 (1.4), p = 0.01). In linear regression models, there were no significant differences in post‐ES constructs after adjusting for clinically relevant covariates.
Conclusions
All individuals experienced significant generalized psychological distress in the pre‐ES period, extending our knowledge of how pregnancy history contributes to parental sequencing outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
- Department of Social Medicine and Center for Bioethics, University of North Carolina, Chapel Hill, North Carolina, USA.
- Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine and the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Evanston, Illinois, USA.
ORCID-Profile: Asha N Talati, Neeta L Vora
Förderung
- NICHD NIH HHS
- Eunice Kennedy Shriver National Institute of Child Health and Human Development
Zitieren
APA
Talati, A. N., Gilmore, K. L., Hardisty, E. E., Lyerly, A. D., Rini, C., & Vora, N. L. (2023). Diagnostic yield and psychological outcomes among women pursuing trio‐exome sequencing: Do women with recurrent anomalous fetal phenotypes experience more negative psychological outcomes?. Prenatal Diagnosis. https://doi.org/10.1002/pd.6318
Vancouver
Talati AN, Gilmore KL, Hardisty EE, Lyerly AD, Rini C, Vora NL. Diagnostic yield and psychological outcomes among women pursuing trio‐exome sequencing: Do women with recurrent anomalous fetal phenotypes experience more negative psychological outcomes?. Prenatal Diagnosis. 2023. doi:10.1002/pd.6318
BibTeX
@article{Talati2023,
author = {Talati, Asha N and Gilmore, Kelly L and Hardisty, Emily E and Lyerly, Anne D and Rini, Christine and Vora, Neeta L},
title = {Diagnostic yield and psychological outcomes among women pursuing trio‐exome sequencing: Do women with recurrent anomalous fetal phenotypes experience more negative psychological outcomes?},
journal = {Prenatal Diagnosis},
year = {2023},
doi = {10.1002/pd.6318}
}
EUVIMED